Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-blocking agents with vasodilating action.

B N Prichard1

  • 1Department of Clinical Pharmacology, University College, London, England.

Journal of Cardiovascular Pharmacology
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term treatment of hypertension with labetalol.

British journal of clinical pharmacology·2015
Same author

Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.

British journal of clinical pharmacology·2015
Same author

Proceedings of the Second Symposium on Labetalol, London, March 1979.

British journal of clinical pharmacology·2015
Same author

An Examination of Some Factors which Influence the Stability of in Vitro Platelet Responses.

Platelets·2010
Same author

Collagen-induced Platelet Activation In Vitro Increases Plasma Catecholamine Concentration.

Platelets·2010
Same author

Problems with Beta Adrenergic Blocking Drugs and other Antihypertensive Drugs.

Proceedings of the Royal Society of Medicine·2010

Newer beta-blockers offer improved vasodilation through multiple mechanisms, including alpha-blockade and beta 2-agonism. These advancements provide enhanced therapeutic options beyond traditional beta-adrenoceptor blockade.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Background:

  • Beta-adrenoceptor-blocking drugs are categorized as nonselective or beta 1-selective.
  • Both drug classes can decrease cardiac output and increase peripheral resistance, reducing blood flow.
  • Some beta-blockers possess intrinsic sympathomimetic activity, including beta 2-mediated vasodilation.

Purpose of the Study:

  • To review the development of beta-blocking drugs with enhanced peripheral vasodilator activity.
  • To explore the mechanisms responsible for peripheral vasodilation in these advanced beta-blockers.

Main Methods:

  • Review of existing literature on beta-adrenoceptor-blocking drugs.
  • Analysis of reported mechanisms for peripheral vasodilation, including alpha-receptor blockade, beta 2-agonism, and independent dilator actions.

Related Experiment Videos

  • Examination of evidence from animal studies and human trials.

    • Main Results:

    • Labetalol was the first beta-blocker developed with significant peripheral vasodilator activity.
    • Multiple mechanisms contribute to vasodilation: alpha-receptor blockade (e.g., labetalol, carvedilol), beta 2-agonism (e.g., celiprolol, dilevalol), and receptor-independent actions (e.g., celiprolol, carvedilol).
    • Prizidolol was withdrawn due to toxicity; other agents like bucindolol, carvedilol, celiprolol, dilevalol, and medroxolol have been described.

    Conclusions:

    • Advanced beta-blocking drugs incorporate peripheral vasodilator activity alongside beta-receptor blockade.
    • Mechanisms of vasodilation are diverse, involving alpha-blockade, beta 2-agonism, or independent pathways.
    • These multiple-action beta-blockers represent a significant advancement in cardiovascular pharmacotherapy.